China Unveils Sweeping 2024 Legislative Plan with Healthcare and Pharma at Forefront
The State Council of China has released its annual legislative work plan for 2024, outlining...
MSD’s Keytruda Adjuvant Treatment for High-Risk Endometrial Cancer Fails to Meet Primary Endpoint
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...
Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip
Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been...
WestGene Biopharma’s Groundbreaking mRNA Vaccine for EB Virus Tumors Gets FDA Green Light
WestGene Biopharma Co., Ltd., a biopharmaceutical company based in Chengdu, has announced that its drug...
RJK Biopharma’s RJK002 Earns Tacit Approval for Amyotrophic Lateral Sclerosis Clinical Trial
Shanghai-based RJK Biopharma Ltd. has announced that its Category 1 drug RJK002 has received tacit...
BioNTech Secures Global Rights to Biotheus Inc.’s Pre-Clinical Bispecific Antibody
Biotheus Inc., a biopharmaceutical company based in China, has announced that its German partner BioNTech...
China Grants Marketing Nod to Ferring Pharmaceuticals’ Rekovelle for Assisted Reproduction
Switzerland-based Ferring Pharmaceuticals Ltd announced that its recombinant human follicle stimulating hormone δ injection, Rekovelle,...
Hong Kong SAR and NMPA Renew Agreements to Boost Drug and Medical Device Regulation
Professor Chung-mau LO, BBS, JP, Secretary for Health of the Hong Kong Special Administrative Region...
Chia Tai Tianqing’s PD-L1 Antibody Benmelstobart Wins NMPA Nod for ES-SCLC
China-based Chia Tai Tianqing has announced that it has received marketing approval from the National...
GSK Shakes Up Leadership with Promotion of Cecilia Qi and Appointment of Sherman Yu
Mike Crichton, Senior Vice President of GlaxoSmithKline (GSK, NYSE: GSK) for the Greater China and...
Sichuan Biokin Pharmaceutical Advances BL-B16D1 to Clinical Trial for Advanced Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...
Bio-Thera Solutions’ PD-1 and ADC Combo Gets NMPA Approval for Clinical Trial in Solid Tumors
Bio-Thera Solutions, Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Sandoz Q1 2024 Results Highlight 6% Growth, Led by Biosimilars and European Strength
Switzerland-based Sandoz (SWX: SDZ) has reported its financial results for the first quarter of 2024,...
Jiangsu QYuns Therapeutics Gets NMPA Green Light for CSU Treatment QX013N
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...
MicroPort MedBot’s Toumai Robot Gets EU Green Light for Broad Surgical Applications
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that its Toumai endoscopic surgery...
MicroPort CardioFlow Medtech’s AltaValve Receives FDA Breakthrough Designation for Mitral Regurgitation Treatment
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...
Laekna’s ActRIIA Monoclonal Antibody LAE102 Gets Green Light from China’s CDE for Obesity Treatment
Sino-US biotech firm Laekna has announced that it has received clinical trial approval from the...
Cancer Diagnostics Firm Mirxes Aims for USD 100 Million in Hong Kong IPO
Mirxes, a Singapore-based company specializing in cancer diagnostics, has refiled a draft prospectus with the...
Astellas Invests USD 90 Million in New US Facility to Boost Research and Commercialization
Japanese pharmaceutical company Astellas Pharma Inc. (TYO: 4503) has inaugurated a state-of-the-art laboratory and office...
Novo Nordisk’s Q1 2024 Global Sales Surge 24% YOY on Strength of GLP-1 Therapies
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) reported a substantial 24% year-on-year (YOY) increase in...